Verastem, Inc. (2VS.F)
| Previous Close | 0.6408 |
| Open | 0.6304 |
| Bid | 0.6368 x 268600 |
| Ask | 0.6492 x 258400 |
| Day's Range | 0.6304 - 0.6564 |
| 52 Week Range | 0.2530 - 1.7845 |
| Volume | |
| Avg. Volume | 550 |
| Market Cap | 134.907M |
| Beta (5Y Monthly) | 0.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3900 |
| Earnings Date | Mar 27, 2023 - Mar 31, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.25 |
- Business Wire
Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
BOSTON, February 02, 2023--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today outlined key strategic priorities and upcoming catalysts to support its lead compound RAF/MEK clamp avutometinib in RAS pathway-driven cancers.
- Zacks
Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock?
Verastem (VSTM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Business Wire
Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock
BOSTON, January 24, 2023--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has entered into a definitive agreement to sell approximately 2.1 million shares of its Series B Convertible Preferred Stock (the "Preferred Stock") to affiliates of BVF Partners L.P. in a private placement to raise aggregate gross proceeds of up to approximately $60 million in two tranches, before deducting fees to the plac
